Basic Information
RNALocate ID: | RLID:11001574 |
RNA Symbol: | hsa-miR-200b-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-200b-3p |
RNA ID: | miRBase:MIMAT0000318 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001685 | Cytoplasm | Colon cancer cells | 20864815 |
RLID:01001686 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
RLID:11001571 | Exosome | Urine | 26576778 |
RLID:11001572 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11001573 | Exosome | Brain tissue | 23382797 |
RLID:11001575 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000067 | Exosome | Breast milk|Colon tissue|Seminal fluid|Tongue tissue | |
RLID-D:11000341 | Microvesicle | Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-200b-3p | Splenic marginal zone lymphoma | MNDR-E-MI-26092 |
MNDR | hsa-miR-200b-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-26093 |
MNDR | hsa-miR-200b-3p | Tongue squamous cell carcinoma | MNDR-E-MI-26094 |
MNDR | hsa-miR-200b-3p | Oral squamous cell carcinoma | MNDR-E-MI-26095 |
MNDR | hsa-miR-200b-3p | Large cell neuroendocrine cancer | MNDR-E-MI-26096 |
MNDR | hsa-miR-200b-3p | Medulloblastoma | MNDR-E-MI-26097 |
MNDR | hsa-miR-200b-3p | Mucosa-associated lymphoid tissue lymphoma | MNDR-E-MI-26098 |
MNDR | hsa-miR-200b-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-26099 |
MNDR | hsa-miR-200b-3p | Ovarian clear cell carcinoma | MNDR-E-MI-26100 |
MNDR | hsa-miR-200b-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-26101 |
MNDR | hsa-miR-200b-3p | Lymphoma non-hodgkin | MNDR-E-MI-26102 |
MNDR | hsa-miR-200b-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-26103 |
MNDR | hsa-miR-200b-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-26104 |
MNDR | hsa-miR-200b-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-26105 |
MNDR | hsa-miR-200b-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-26106 |
MNDR | hsa-miR-200b-3p | Her2-receptor positive breast cancer | MNDR-E-MI-26107 |
MNDR | hsa-miR-200b-3p | Triple negative breast cancer | MNDR-E-MI-26108 |
MNDR | hsa-miR-200b-3p | Breast cancer luminal | MNDR-E-MI-26109 |
MNDR | hsa-miR-200b-3p | Androgen-independent prostate cancer | MNDR-E-MI-26110 |
MNDR | hsa-miR-200b-3p | Gastric cancer | MNDR-E-MI-26111 |
MNDR | hsa-miR-200b-3p | Gastric lymphoma | MNDR-E-MI-26112 |
MNDR | hsa-miR-200b-3p | Alzheimer disease | MNDR-E-MI-26113 |
MNDR | hsa-miR-200b-3p | Bladder cancer | MNDR-E-MI-26114 |
MNDR | hsa-miR-200b-3p | Head and neck cancer | MNDR-E-MI-26115 |
MNDR | hsa-miR-200b-3p | Ataxia telangiectasia | MNDR-E-MI-26116 |
MNDR | hsa-miR-200b-3p | Cardiovascular disease | MNDR-E-MI-26117 |
MNDR | hsa-miR-200b-3p | Lung cancer | MNDR-E-MI-26118 |
MNDR | hsa-miR-200b-3p | Endometrial cancer | MNDR-E-MI-26119 |
MNDR | hsa-miR-200b-3p | Parkinson disease | MNDR-E-MI-26120 |
MNDR | hsa-miR-200b-3p | Basal-like breast cancer | MNDR-E-MI-26121 |
MNDR | hsa-miR-200b-3p | Cancer | MNDR-E-MI-26122 |
MNDR | hsa-miR-200b-3p | Thyroid cancer | MNDR-E-MI-26123 |
MNDR | hsa-miR-200b-3p | Pituitary neoplasms | MNDR-E-MI-26124 |
MNDR | hsa-miR-200b-3p | Pancreatic cancer | MNDR-E-MI-26125 |
MNDR | hsa-miR-200b-3p | Melanoma | MNDR-E-MI-26126 |
MNDR | hsa-miR-200b-3p | Rectum adenocarcinoma | MNDR-E-MI-26127 |
MNDR | hsa-miR-200b-3p | Nephroblastoma | MNDR-E-MI-26128 |
MNDR | hsa-miR-200b-3p | Colon cancer | MNDR-E-MI-26129 |
MNDR | hsa-miR-200b-3p | Ischemic attack transient | MNDR-E-MI-26130 |
MNDR | hsa-miR-200b-3p | Colon adenocarcinoma | MNDR-E-MI-26131 |
MNDR | hsa-miR-200b-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-26132 |
MNDR | hsa-miR-200b-3p | Familial ovarian cancer | MNDR-E-MI-26133 |
MNDR | hsa-miR-200b-3p | Acromegaly | MNDR-E-MI-26134 |
MNDR | hsa-miR-200b-3p | Kidney cancer | MNDR-E-MI-26135 |
MNDR | hsa-miR-200b-3p | Endometrial adenocarcinoma | MNDR-E-MI-26136 |
MNDR | hsa-miR-200b-3p | Endometrial endometrioid carcinoma | MNDR-E-MI-26137 |
MNDR | hsa-miR-200b-3p | Endometriosis | MNDR-E-MI-26138 |
MNDR | hsa-miR-200b-3p | Carcinoma ductal breast | MNDR-E-MI-26139 |
MNDR | hsa-miR-200b-3p | Glioblastoma | MNDR-E-MI-26140 |
MNDR | hsa-miR-200b-3p | Astrocytoma | MNDR-E-MI-26141 |
MNDR | hsa-miR-200b-3p | Glioma | MNDR-E-MI-26142 |
MNDR | hsa-miR-200b-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-26143 |
MNDR | hsa-miR-200b-3p | Breast carcinoma | MNDR-E-MI-26144 |
MNDR | hsa-miR-200b-3p | Uterine cancer | MNDR-E-MI-26145 |
MNDR | hsa-miR-200b-3p | Cervical adenocarcinoma | MNDR-E-MI-26146 |
MNDR | hsa-miR-200b-3p | Gastric adenocarcinoma | MNDR-E-MI-26147 |
MNDR | hsa-miR-200b-3p | Cervical squamous cell carcinoma | MNDR-E-MI-26148 |
MNDR | hsa-miR-200b-3p | Pituitary adenoma | MNDR-E-MI-26149 |
MNDR | hsa-miR-200b-3p | Lung squamous cell carcinoma | MNDR-E-MI-26150 |
MNDR | hsa-miR-200b-3p | Carcinoma lung non-small-cell | MNDR-E-MI-26151 |
MNDR | hsa-miR-200b-3p | Lung adenocarcinoma | MNDR-E-MI-26152 |
MNDR | hsa-miR-200b-3p | Ovarian carcinoma | MNDR-E-MI-26153 |
MNDR | hsa-miR-200b-3p | Bladder urothelial carcinoma | MNDR-E-MI-26154 |
MNDR | hsa-miR-200b-3p | Pancreatic adenocarcinoma | MNDR-E-MI-26155 |
MNDR | hsa-miR-200b-3p | Carcinoma renal cell | MNDR-E-MI-26156 |
MNDR | hsa-miR-200b-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-26157 |
MNDR | hsa-miR-200b-3p | Clear cell renal cell carcinoma | MNDR-E-MI-26158 |
MNDR | hsa-miR-200b-3p | Allergic rhinitis | MNDR-E-MI-26159 |
MNDR | hsa-miR-200b-3p | Biliary tract cancer | MNDR-E-MI-26160 |
MNDR | hsa-miR-200b-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-26161 |
MNDR | hsa-miR-200b-3p | Cholangiocarcinoma | MNDR-E-MI-26162 |
MNDR | hsa-miR-200b-3p | Lung small cell carcinoma | MNDR-E-MI-26163 |
MNDR | hsa-miR-200b-3p | Gastric carcinoma | MNDR-E-MI-26164 |
MNDR | hsa-miR-200b-3p | Testicular germ cell cancer | MNDR-E-MI-26165 |
MNDR | hsa-miR-200b-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-26166 |
MNDR | hsa-miR-200b-3p | Adenoma | MNDR-E-MI-26167 |
MNDR | hsa-miR-200b-3p | Breast invasive carcinoma | MNDR-E-MI-26168 |
MNDR | hsa-miR-200b-3p | Hepatocellular carcinoma | MNDR-E-MI-26169 |
MNDR | hsa-miR-200b-3p | Familiar ovarian carcinoma | MNDR-E-MI-26170 |
MNDR | hsa-miR-200b-3p | B-cell lymphoma | MNDR-E-MI-26171 |
MNDR | hsa-miR-200b-3p | Malignant pleural mesothelioma | MNDR-E-MI-26172 |
MNDR | hsa-miR-200b-3p | Periodontitis | MNDR-E-MI-26173 |
MNDR | hsa-miR-200b-3p | Hodgkin lymphoma | MNDR-E-MI-26174 |
MNDR | hsa-miR-200b-3p | Ulcerative colitis | MNDR-E-MI-26175 |
MNDR | hsa-miR-200b-3p | Burkitt lymphoma | MNDR-E-MI-26176 |
MNDR | hsa-miR-200b-3p | Crohn disease | MNDR-E-MI-26177 |
MNDR | hsa-miR-200b-3p | Skin cutaneous melanoma | MNDR-E-MI-26178 |
MNDR | hsa-miR-200b-3p | Skin melanoma | MNDR-E-MI-26179 |
MNDR | hsa-miR-200b-3p | Acute myelogenous leukemia | MNDR-E-MI-26180 |
MNDR | hsa-miR-200b-3p | Colorectal cancer | MNDR-E-MI-26181 |
MNDR | hsa-miR-200b-3p | Multiple myeloma | MNDR-E-MI-26182 |
MNDR | hsa-miR-200b-3p | Type 1 diabetes mellitus | MNDR-E-MI-26183 |
MNDR | hsa-miR-200b-3p | Ovarian epithelial cancer | MNDR-E-MI-26184 |
MNDR | hsa-miR-200b-3p | Autoimmune diseases | MNDR-E-MI-26185 |
MNDR | hsa-miR-200b-3p | Graft vs host disease | MNDR-E-MI-26186 |
MNDR | hsa-miR-200b-3p | Prostatic neoplasms | MNDR-E-MI-26187 |
MNDR | hsa-miR-200b-3p | Chronic pain | MNDR-E-MI-26188 |
MNDR | hsa-miR-200b-3p | Breast cancer her3+ negative | MNDR-E-MI-26189 |
MNDR | hsa-miR-200b-3p | Cholestatic liver injury | MNDR-E-MI-26190 |
MNDR | hsa-miR-200b-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-26191 |
MNDR | hsa-miR-200b-3p | Tubulovillous adenoma | MNDR-E-MI-26192 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ADAM12 | Homo sapiens | RR00040359 |
TOP